Novocure Stock Forecast, Price & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have increased by 81.2% and is now trading at $122.10.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Novocure.

Novocure Ltd (NASDAQ:NVCR) announced its earnings results on Thursday, October, 29th. The medical equipment provider reported $0.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.05. The medical equipment provider earned $132.70 million during the quarter, compared to analyst estimates of $120.02 million. Novocure had a return on equity of 5.14% and a net margin of 2.88%. The firm's revenue was up 44.1% on a year-over-year basis. During the same period last year, the business posted $0.02 earnings per share.
View Novocure's earnings history.

10 Wall Street analysts have issued 12 month target prices for Novocure's shares. Their forecasts range from $58.00 to $150.00. On average, they anticipate Novocure's share price to reach $99.67 in the next year. This suggests that the stock has a possible downside of 18.4%.
View analysts' price targets for Novocure.

Novocure saw a increase in short interest in September. As of September 30th, there was short interest totaling 5,330,000 shares, an increase of 41.4% from the September 15th total of 3,770,000 shares. Based on an average daily trading volume, of 961,000 shares, the days-to-cover ratio is currently 5.5 days. Currently, 6.4% of the company's shares are short sold.
View Novocure's Short Interest.

Some companies that are related to Novocure include Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), FRESENIUS SE &/S (FSNUY), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Penumbra (PEN), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Hill-Rom (HRC), Haemonetics (HAE), Nevro (NVRO) and Globus Medical (GMED).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.41%), Kornitzer Capital Management Inc. KS (0.17%), Peregrine Capital Management LLC (0.13%), Scout Investments Inc. (0.10%), State of New Jersey Common Pension Fund D (0.06%) and Taylor Frigon Capital Management LLC (0.05%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, BNP Paribas Arbitrage SA, State of New Jersey Common Pension Fund D, CWM LLC, Envestnet Asset Management Inc., Kornitzer Capital Management Inc. KS, Amalgamated Bank, and IFP Advisors Inc. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure.

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Hodges Capital Management Inc., Rhenman & Partners Asset Management AB, Eagle Global Advisors LLC, Standard Life Aberdeen plc, Exchange Traded Concepts LLC, IBM Retirement Fund, and NewFocus Financial Group LLC.
View insider buying and selling activity for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $122.10.

Novocure has a market capitalization of $12.34 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

The official website for Novocure is www.novocure.com.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]